Market Insights

Close

Subscribe to our newsletter

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.

RESEARCH AND NEWS

Empowering investors with access to the best research, experts and opportunities.

SUBSCRIBE

THIS WEEK'S NEWS

One of the most advanced cancer therapies on the ASX, Prescient Therapeutics’ (ASX: PTX) PTX-100 is currently in Phase 2a trials for its first targeted cancer, Cutaneous T-Cell Lymphoma (CTCL), which many clinicians see as a death sentence in the…
| 8 September 2026

WEBCASTS AND MEDIA

NEWS

RESEARCH

Is this Australia’s next biotech success story?
Aussie medtech readies ASX IPO to combat world’s second-biggest killer
Aussie company solving military supply issues for the US, UK and Ukraine
How this ASX biotech could potentially address 22% of all cancers worldwide
The critical mineral behind AI chips: Why existing suppliers can’t meet demands
Aussies in Silicon Valley Winning Business Off Databricks and Snowflake